Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Multiple myeloma (MM) is a malignant neoplasm characterized by the presence of monoclonal immunoglobulins in blood and/or urine and the accumulation of plasma cells in the bone marrow 1. This can ultimately lead to end-organ damage including marrow failure, skeletal or bone lesions, renal failure, hypercalcemia, anemia, and infections 1. MM is the second most common hematologic malignancy in the United States (US), with 35,730 expected new cases and 12,590 deaths in 2023 1, 2. Two thirds of patients with newly diagnosed MM (NDMM) are aged over 65 years (median age at diagnosis is 69) and the median age at death is 75 years 3.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 13, 2023 Category: Hematology Authors: Lucio Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z. Fu, Marie-H élène Lafeuille, Philippe Thompson-Leduc, Vipin Khare, John Reitan, Gary Milkovich, Shuchita Kaila, Faith Davies, Saad Z. Usmani Tags: Original Study Source Type: research